Tyra Biosciences, Inc. (TYRA) · Sep 14, 2026 · Share issuance
$400M equity raise — ~18.2M shares and pre-funded warrants; $400M gross proceeds
Tyra secures $400 million for its FGFR pipeline, but the raise adds roughly 18.2 million shares and warrants to the capital base.
Tyra is a clinical-stage biotech advancing FGFR-targeted medicines, with oral dabogratinib moving through Phase 2 studies in bladder cancer and pediatric skeletal dysplasia. The company had recently said its $353.9 million cash, cash equivalents and marketable securities could fund operations into the second half of 2028, while initial SURF302 data had become an immediate development milestone.
The filing materially strengthens funding, but it is not free capital. Tyra priced an underwritten offering of 9,079,000 common shares plus pre-funded warrants for another 9,078,529 shares, targeting approximately $400.0 million of gross proceeds.
| Measure | Filing figure | Comparison |
|---|---|---|
| Common shares sold | 9.079 million | $22.03 per share |
| Pre-funded warrant shares | 9.079 million | $22.029 per warrant; $0.001 exercise price |
| Total potential shares issued | 18.158 million | Versus 59.663 million common shares outstanding at June 30, 2026 |
| Gross proceeds | $400.0 million | Before discounts, commissions and expenses |
| Expected closing | September 15, 2026 | Subject to customary conditions |
The size is the real signal. Relative to the 59.7 million common shares outstanding at June 30, the offering represents roughly 30% additional share-equivalent issuance before considering other dilution. The pre-funded warrants are economically close to shares because they are immediately exercisable at a nominal price and do not expire.
This appears designed to fund a broader clinical push rather than solve an immediate liquidity problem. Tyra already had a stated runway into the second half of 2028, so the raise likely gives the company more flexibility to advance multiple programs, absorb rising trial costs and reduce dependence on another near-term financing. That benefit is balanced by substantial dilution, and the filing does not disclose a new clinical result or a change to the underlying probability of success. The recent ATM expansion made additional equity financing partly foreseeable, but this $400 million underwritten transaction is materially larger than that previously disclosed capacity.
Bottom line: This is a meaningful balance-sheet event, not a clinical validation event. Tyra buys considerable development flexibility ahead of its pipeline milestones, but shareholders pay for it through a large new share-equivalent issuance.
Offering close, September 15, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!